Wetting agent formulation

ABSTRACT

A first alternative to a composition for preventing or retarding degradation of a functional coating on a medical device comprising an antioxidant selected from gallic acid or a derivative thereof. A second alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes carboxymethyl cellulose or a derivative or salt thereof. The use of the compositions for preventing or retarding degradation of a functional coating on a medical device from reactive species generated during exposure of radiation, and a wetting agent comprising the compositions, are also provided. The wetting agent prevents or retards the hydrolytic degradation of the coating during the intended shelf-life of the wetted coated product.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Divisional of U.S. patent application Ser. No.16/324,437, filed Feb. 8, 2019, which is a national stage application ofInternational patent application PCT/EP2017/000970, filed on Aug. 9,2017, which claims priority of foreign European patent application No.EP 16001766.1, filed on Aug. 9, 2016, the disclosures of which areincorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to a composition for preventing orretarding degradation of a functional coating on a medical device, theuse of the composition, and a wetting agent comprising the composition.

It is well-known to coat medical devices with a lubricant to the outersurface, in particular to facilitate insertion into or removal from thebody, e.g. blood vessels, digestive organs and the urinary system. Suchlubricious properties are also desired to minimize tissue damage duringinsertion or removal. Usually, medical devices may be provided with ahydrophilic coating on which a wetting fluid is applied. The wettingfluid protects the coating from drying out and thereby maintains thelubricious properties of the coating. Examples of wetting fluids arewater, mixtures of water and organic solvents, a body fluid, and aqueoussolutions of salts, e.g. a saline solution having physiologicalosmolarity.

Medical devices can be wetted immediately prior to use or can be storedin the wetting liquid. In particular, it is desirable to provide aready-to-use medical device, wherein the medical device with ahydrophilic coating is in a sterile package that contains enough wettingliquid to keep the coating wetted and thereby lubricious.

Suitable sterilization techniques for medical devices are well-known tothe skilled person, such as autoclaving or irradiation. Duringsterilization, reactive intermediates can be formed, which may attackthe hydrophilic coating of the medical device. Furthermore, mosthydrophilic coatings lose their water retention and lubriciousproperties when the coatings are stored for an extended period of timeand/or after sterilization using autoclaving or irradiation.

WO-A-00/30696 describes a method for sterilizing a medical devicecomprising a hydrophilic coating by irradiation. It was found that thewater retention can be increased and the coefficient of friction can bekept low by adding hydrophilic polymers to the wetting liquid.

WO-A-2007/137699 discloses the use of a compound selected from aliphaticcompounds, alicyclic compounds and antioxidants for protecting ahydrophilic coating which is sterilized by irradiation, in particularγ-radiation or Electron-beam (E-beam) radiation.

WO-A-2013/017547 is directed to the use of a wetting liquid, which maycomprise water in an amount of 0 to 4.9 wt % and has a boiling pointhigher than 100° C and a viscosity lower than 500 mPa×s.

WO-A-2006/037321 is directed to a medical device having a wettedhydrophilic coating and which is in a ready-to-use form. The wettedhydrophilic coating comprises a coating composition comprising ahydrophilic polymer and a wetting agent comprising water and one or morelubricants.

WO-A-2006/117372 describes sterilization of medical devices having awetted hydrophilic coating using radiation. It was found that whenadding hydrophilic polymers to the storage medium prior to sterilizationa high water retention and a low friction is maintained when the medicaldevice is stored in water.

WO-A-2011/076217 discloses a medical device having a hydrophilic coatingand being sterilized while in contact with a swelling medium comprisinga low molecular polyol and a separate buffer. The pH is in the range offrom 4 to 7.4. Furthermore, ascorbic acid may be added as a stabilizingagent, but that depends on the substrate, type of hydrophilic coatingand gamma irradiation dosage.

WO-A-2010/003419 relates to a medical device having a hydrophiliccoating and being sterilized while in contact with a liquid comprising ahydrophilic polymer and a separate buffer.

WO-A-2012/085107 is directed to a hydrophilic catheter assemblyincluding a wetting fluid. The wetting fluid is preferably an aqueousliquid, such as sterile water or saline.

WO-A-2008/151074 discloses a lubricant for medical devices which issuitable for radiation sterilization.

WO-A-00/47494 relates to a storage package which contains a medicaldevice having a coated surface which exhibits a reduced friction whenwetted.

WO-A-2007/065721 and WO-A-2007/065722 describe a hydrophilic coatingcomposition which when cured results in a hydrophilic coating. It wasfound that a lubricious coating with a prolonged and improved dry-outtime may be obtained when a polyelectrolyte is included in thehydrophilic coating from which said lubricious coating ins formed byapplying a wetting fluid.

However, the compositions of the above-cited prior art are highlyspecific and can be used only for a limited group of hydrophiliccoatings. Furthermore, the particular components present in thecomposition have to be selected depending on the hydrophilic coating orthe base solution.

The object of the present invention is to provide a composition whichovercomes the disadvantages of the prior art and which is able toprevent or retard degradation of a functional coating on a medicaldevice, which has improved properties, in particular is non-toxic, easyto prepare, radiation sterilizable, cheap and cost effective, and can beused for a large variety of functional coatings.

This object is achieved by a composition for preventing or retardingdegradation of a functional coating on a medical device comprising anantioxidant selected from gallic acid or a derivative thereof.

This object is also achieved by a composition for preventing orretarding degradation of a functional coating on a medical devicecomprising carboxymethyl cellulose or a derivative or salt thereof.

The object is further achieved by the use of the composition forpreventing or retarding degradation of a functional coating on a medicaldevice from reactive species generated during exposure of radiationand/or from hydrolytic degradation, and a wetting agent comprising thecomposition.

Preferred embodiments are set forth in the subclaims 2 to 4 and 5 to 20.

The composition in accordance with the present invention can be used fora variety of hydrophilic coating systems, gels and material substrates.The variation in the additional components of the composition inaccordance with the present invention allows further enhancement of thewetting agent performance in relation to solubility stability andcoating stability.

In addition, the composition in accordance with the present invention isnon-toxic, can be easily prepared and is radiation sterilizable.Furthermore, the composition can be used in a variety of differentwetting agents, independently on the base solutions. Unexpectedly, thecomposition in accordance with the present invention prevents or retardsthe degradation of a functional coating on a medical device fromreactive species formed during exposure to radiation, even at anirradiation energy of up to 50 kGy.

When a medical device with a functional coating is sterilized byirradiation, highly reactive intermediates may be formed from water,e.g. ·OH, H₂O⁺, superoxide (HO₂/O₂−, H₂O₂. These reactive moieties maycause reactions that are detrimental to the coating of the medicaldevice. The composition of the present invention is more reactivetowards a reactive moiety formed from water due to the irradiation, thanthe coating. The composition in accordance with the present inventionmay be furthermore able to inactivate a radical which may be formed in apolymer in the coating and thereby preventing uncontrolled and/orexcessive crosslinking of the coating, and/or chain scission of thecoating polymer, and/or delamination from the substrate.

The composition in accordance with the present invention is formulatedto act as a highly protective agent for all types of functional coatingsystems subjected to high radiation levels when the coating substrate,i.e. the medical device, is subjected or exposed in a wetted environmentcomprising the composition. Further, since the composition in accordancewith the present invention acts as protective agent, the functionalcoating of the medical device can be formed by crosslinking via an UVinitiator, heat, γ-ray, X-ray or E-beam. The composition of the presentinvention is not limited to a particular coating material type or curingsystem, but can be used for any functional coating.

In addition, the composition in accordance with the present inventionalso acts as highly protective agent for hydrolytic degradation, inparticular long term hydrolytic degradation. The wetting agent inaccordance with the present invention is particularly suitable forprotecting a gel like low delicate (hydrated) interpenetrating polymernetwork from irradiation and also provides hydrolytic stability.

The present invention provides a composition and a wetting agentcomprising the composition which is mobile and in a liquid state,preferably the wetting agent is an aqueous wetting agent containingfully dissolved gallic acid or an ester, amide or oxadiazole derivativeof gallic acid and/or CMC or a salt thereof and provides intimatecontact with free moving hydrophilic polymer chains of the coating of amedical device. The composition in accordance with the present inventionis mobile and free flowing at the surface of the coating.

The composition of the present invention allows preventing or retardingdegradation of a functional coating from both, irradiation andhydrolytic degradation. In particular, the composition and the wettingagent of the present invention is capable of protecting even polymerssuch as gel networks, e.g. lightly crosslinked gel networks, andhydrophilic coatings, while in an aqueous environment and under extremeirradiation conditions. The composition and the wetting agent of thepresent invention further provide hydrolytic stability during theintended shelf-life of a wetted coated product.

The term “functional coating” includes hydrophilic coatings,antithrombogenic coatings, gel coatings, hydrophilic polymer coatings,polyvinylalcohol coatings, coatings for contact lenses, coatings basedon water soluble polymers used especially in drug delivery systems, suchas hydrogels, cellulose ethers, povidone, polyethylene glycol,polyacrylamides, polyacrylic acid copolymers, Polylactide-co-Glycolide(PGLA) and derivatives thereof. In a preferred embodiment in combinationwith any of the above or below embodiments, the functional coating is ahydrophilic coating.

In a first alternative, the composition for preventing or retardingdegradation of a functional coating on a medical device comprises anantioxidant selected from gallic acid or a derivative thereof.

Gallic acid is a benzoic acid having the following structure:

The IUPAC name is: 3,4,5-trihydroxybenzoic acid.

The derivative of gallic acid is an ester, amide or oxadiazolederivative of gallic acid.

The term “ester derivative of gallic acid” refers to an ester reactionproduct of an alcohol and gallic acid. The term “amide derivative ofgallic acid” refers to the reaction product of an amine and gallic acid.The term “oxadiazole derivative of gallic acid” refers to the reactionproduct of oxadiazole and gallic acid.

In a preferred embodiment in combination with any of the above or belowembodiments, in the composition in accordance with the presentinvention, the ester derivative of gallic acid is a reaction product ofgallic acid and an aliphatic C1 to C16 alcohol, more preferably areaction product of gallic acid and an aliphatic C1 to C12 alcohol. Mostpreferably, the ester derivative of gallic acid is selected from propylgallate, methyl gallate, ethyl gallate, octyl gallate and lauryl gallateor mixtures thereof, in particular, the ester derivative of gallic acidis propyl gallate.

The term “aliphatic alcohol” refers to a saturated linear or branchedalcohol.

Propyl gallate is the reaction product of gallic acid and propanol andhas the following structure:

Other commonly used names are: n-propyl gallate, propyl3,4,5-trihydroxybenzoate, gallic acid propyl ester,3,4,5-trihydroxybenzoic acid propyl ester,3,4,5-trihydroxybenzene-1-propylcarboxylate, CAS No 121-79-9.

In a preferred embodiment in combination with any of the above or belowembodiments, in the composition in accordance with the presentinvention, the amide derivative of gallic acid is selected from gallicN,N-dimethylamide, gallic naphtylamide or mixtures thereof.

The oxadiazole derivative of gallic acid has the following structure:

In a preferred embodiment in combination with any of the above or belowembodiments, in the first alternative, the composition in accordancewith the present invention, gallic acid or a derivative thereof ispresent in an amount of 0.001 to 5% by weight, more preferably 0.01 to2% by weight, most preferably 0.05 to 0.5% by weight, in particular 0.1to 0.2% by weight, based on the total weight of the composition.

In a second alternative, the composition of the present inventioncomprises carboxymethyl cellulose or a derivative or salt thereof.

Carboxymethyl cellulose (CMC) is a cellulose derivative, wherein some ofthe hydroxyl groups of the glucopyranose monomers that form thecellulose backbone are replaced with carboxymethyl groups (—CH₂—COOH).It is often used as its sodium salt, sodium carboxymethyl cellulose.

Carboxymethyl cellulose has the following structure:

In a preferred embodiment in combination with any of the above or belowembodiments, in the second alternative, the composition comprises a saltof carboxymethyl cellulose, more preferably the sodium salt ofcarboxymethyl cellulose. In sodium carboxymethyl cellulose R of theabove structural formula is CH₂CO₂Na. Other commonly used names aresodium cellulose glycolate, Na—CMC, cellulose gum, sodium CMC, CAS No9004-32-4.

The chemical formula of sodium CMC is[C₆H₇O₂(OH)_(x)(OCH₂COONa)_(y)]_(n), where n is the degree ofpolymerization; x is 1.50 to 2.80; y is 0.2 to 1.50; x+y is 3.0 (y=degree of substitution).

In a further preferred embodiment of the second alternative incombination with any of the above or below embodiments, carboxymethylcellulose or a derivative or salt thereof is present in an amount of 0.1to 10% by weight, more preferably 0.2 to 7% by weight, particularlypreferably 0.2 to 5% by weight, in particular 1 to 5% by weight, basedon the total weight of the composition. Preferably, carboxymethylcellulose is present as the sodium salt, i.e. Na—CMC.

In another preferred embodiment in combination with any of the above orbelow embodiments, the composition of the second alternative furthercomprises gallic acid or a derivative thereof, more preferably propylgallate. Gallic acid derivates are as described above.

In a preferred embodiment in combination with any of the above or belowembodiments, in the composition in accordance with the present inventionof the second alternative, gallic acid or a derivative thereof ispresent in an amount of 0.001 to 1% by weight, more preferably 0.01 to0.5% by weight, in particular 0.02 to 0.2% by weight, based on the totalweight of the composition.

In a preferred embodiment in combination with any of the above or belowembodiments, the composition in accordance with the present inventionfurther comprises an aqueous or oil based base solution or a lipid mediaor a combination thereof.

The term “aqueous solution” refers to any solution wherein water is themain component, i.e. is present in at least 50% by weight, base on thetotal weight of the aqueous solution.

The term “oil based solution” refers to a solution comprising one ormore oils. Preferably, the oil based solution comprises polyethyleneglycol, propylene glycol, glycerol and/or polyvinyl alcohol. Essentialoils may be included in up to 0.5% by weight, based on the oil basedsolution. If an oil based solution is used, the oil based solution maybe present in an amount of up to 49.8% by weight, based on the totalcomposition.

In a preferred embodiment in combination with any of the above or belowembodiments, the aqueous base solution is selected from distilled water,deionized water, reverse osmosis water, filtered water or a salinesolution. More preferably, the aqueous base solution is a salinesolution, in particular a saline solution having physiologicalosmolarity.

In a further preferred embodiment in combination with any of the aboveor below embodiments, the aqueous base solution is present in an amountof 50 to 99.99% by weight, more preferably 85 to 99.8% by weight, inparticular 85 to 94% by weight, based on the total weight of thecomposition.

In a further preferred embodiment in combination with any of the aboveor below embodiments, the aqueous base solution is a saline solutionhaving physiological osmolarity and is present in an amount of 85 to 94%by weight, based on the total weight of the composition.

In a preferred embodiment in combination with any of the above or belowembodiments, the composition in accordance with the present invention ispresent as a suspension within and/or around the functional coating. Theterm “around” as used herein has the meaning of “in the vicinity” of thecoating.

In a further preferred embodiment in combination with any of the aboveor below embodiments, the composition of the present invention of thefirst alternative further comprises a stabilizer and/or a buffersolution.

In a preferred embodiment in combination with any of the above or belowembodiments, the composition of the present invention of the secondalternative further comprises a stabilizer, a solution enhancer and/or abuffer solution.

In another preferred embodiment in combination with any of the above orbelow embodiments, the stabilizer is selected from polylactams, such aspolyvinylpyrrolidone (PVP), polyurethanes, homo- and copolymers ofacrylic and methacrylic acid, polyvinyl alcohols, polyvinylethers,maleic anhydride based copolymers, polyesters, such as polylactides,polyglycolides, polycaprolactones, and polynucleotides, vinylamines,polyethyleneimines, polyethyleneoxides, polycarboxylic acids,polyamides, polyanhydrides, polyphosphazenes, cellulosics, such asmethyl cellulose, carboxymethyl cellulose, hydroxymethylcellulose,hydroxyxpropylcellulose and other polysaccharides, such as chitosans,hyaluronic acids, alginates, gelatins, chitins, heparins, and dextrans,polypeptides/proteins, such as collagens, fibrins, elastins, andalbumin. Of these, PVP is particularly preferred.

In a further preferred embodiment in combination with any of the aboveor below embodiments, PVP is present in the composition of the presentinvention in an amount of 0.1 to 40% by weight, more preferably 3 to 20%by weight, most preferably 4 to 12% by weight, and in particular 7 to12% by weight, based on the total weight of the composition.

As gallic acid and derivatives thereof have a limited solubility inwater, a solution enhancer may be added to the composition in accordancewith the present invention. In a preferred embodiment in combinationwith any of the above or below embodiments, the solution enhancer isselected from a polyol, more preferably ethylene glycol, diethyleneglycol, propylene glycol, glycerol, in particular propylene glycol.

Under certain conditions and concentrations the carboxymethyl celluloseor salt thereof and/or the esters of gallic acid may recrystallize outof the solution overtime. When a stabilizer, in particular in theabove-mentioned concentrations, is added, no recrystallization occursand homogeneity of the solution is maintained.

In a further preferred embodiment in combination with any of the aboveor below embodiments, the solution enhancer, preferably propyleneglycol, is present in the composition of the present invention in anamount of 0.1 to 49.8% by weight, more preferably 1 to 20% by weight, inparticular 2 to 10% by weight, based on the total weight of thecomposition.

As indicated above, the esters of gallic acid have limited solubility inwater, e.g. the solubility of propyl gallate is 3.5 mg/mL. Furthermore,the dissolution rates are slow at room temperature. When adding apolyol, such as propylene glycol, the dissolution rate significantlyincreases without the necessity of heat. In a preferred embodiment incombination with any of the above or below embodiments, the weight ratioof water or saline solution to propylene glycol is 1.0 to 0.3 to 1.0 to1.3, preferably 1.0:0.7.

If a wetting agent is heated to 45° C and greater, the miscibility ofpropyl gallate increases. However, after cooling propyl gallate canprecipitate out of the solution to form low order structure entitiesthat resemble needle lattice structures. The addition of propyleneglycol prevents or eliminates the necessity of elevating the temperatureof the solution. Adding a component to a solution at elevatedtemperature can generate a super-saturated solution, i.e. the solutioncontains more of the dissolved component than under normal roomtemperature conditions. On cooling a super-saturated solution, thedissolved component can precipitate out of the solution. With theaddition of propylene glycol, elevation of the temperature is no longerrequired as it increases the dissolvability of the solution for thatcomponent. The addition of propylene glycol therefore permits dissolvingof gallic acid or a derivative thereof at low and ambient temperatures.

In the case where glycerol is employed, it may be necessary to add someheat to the solution in order to achieve full dissolution of the propylgallate. Further, the sequence of the mixing steps and its effect on therelative dissolution of propyl gallate when all component concentrationsand temperature are kept constant, is as follows:

-   -   Addition of propylene glycol to propyl gallate, then addition of        saline or distilled water: fast reaction (high rate of        dissolution of propyl gallate);    -   Addition of saline/distilled water to propyl gallate, then        addition of propylene glycol: slow reaction (low rate of        dissolution of propyl gallate);    -   Addition of propylene glycol to saline/distilled water, then        addition of propyl gallate: fast reaction (high rate of        dissolution of propyl gallate);    -   Employing glycerol instead of propylene glycol: slow reaction        (low rate of dissolution of propyl gallate).

The polyol, e.g. propylene glycol, further functions as antimicrobialand antifungal agent and therefore delivers antimicrobial and antifungalproperties to the composition in accordance with the present invention.

In another preferred embodiment in combination with any of the above orbelow embodiments, the buffer solution has a pH of 2.0 to 7.4, morepreferably 3.0 to 6.5, in particular 3.0 to 4.0. The buffer solution isadded to generate solution stability with regard to pH and prevent theesters of gallic acid from recrystallization. Suitable buffers includemonocarboxylic acids, such as formic acid, acetic acid, propionic acid,3-hydroxypropionic acid, 2,3-dihydroxypropionic acid, gluconic acid,benzoic acid, cinnamic acid, lactic acid, mandelic acid, glycolic acid,phenylacetic acid, chlorobenzoic acid, naphtoic acid, toluic acid,N-acetylglycine; dicarboxylic acids, such as oxalic acid, malonic acid,succinic acid, glutaric acid, adipic acid, phthalic acid, isophthalicacid, terephthalic acid, malic acid, tartaric acid, itaconic acid, andfumaric acid; tri- and tetracarboxylic acids, such as citric acid and1,2,3,4-butanetetracarboxylic acid; amino acids, such as tryptophan,aspartic acid, glutamic acid, aminobenzoic acid, glycylglycine,glycylglycylglycine, glutathione, N-phenylglycine, carnosine, niacin;aminosulfonic acids; and inorganic acids, such as hydrofluoric acid,cyanic acid and nitrous acid.

In a preferred embodiment in combination with any of the above or belowembodiments, the composition in accordance with the present inventioncomprises 0.01 to 2% by weight of propyl gallate, 0.1 to 40% by weightof PVP, and 0.1 to 49.8% by weight of propylene glycol; more preferably0.05 to 0.5% by weight of propyl gallate, 3 to 20% by weight of PVP, and1 to 20% by weight of propylene glycol; in particular 0.1 to 0.2% byweight of propyl gallate, 4 to 12% by weight of PVP, and 2 to 10% byweight of propylene glycol. Particularly preferable is a compositioncomprising 0.1 to 0.2% by weight of propyl gallate, 4 to 12% by weightof PVP, and 2 to 10% by weight of propylene glycol and a buffer having apH of 4 to 5.

In another preferred embodiment in combination with any of the above orbelow embodiments, the composition in accordance with the presentinvention comprises 0.1 to 10% by weight of sodium carboxymethylcellulose, 0 to 1% by weight of propyl gallate, and 1 to 20% by weightof propylene glycol; more preferably 0.2 to 7% by weight of sodiumcarboxymethyl cellulose, 0.01 to 1% by weight of propyl gallate, and 1to 15% by weight of propylene glycol; in particular 0.2 to 5% by weightof sodium carboxymethyl cellulose, 0.02 to 0.2% by weight of propylgallate, and 2 to 10% by weight of propylene glycol, based on the totalweight of the composition. Particularly preferable is a compositioncomprising 0.2 to 2% by weight of sodium carboxymethyl cellulose, 0.02to 0.2% by weight of propyl gallate, and 2 to 10% by weight of propyleneglycol, based on the total weight of the composition, and a bufferhaving a pH of 4 to 5. Alternatively, particularly preferable is anembodiment composition comprising 2 to 5% by weight of sodiumcarboxymethyl cellulose, 0% by weight of propyl gallate, and 2 to 10% byweight of propylene glycol, based on the total weight of thecomposition, and a buffer having a pH of 4 to 5.

In a further preferred embodiment in combination with any of the aboveor below embodiments, the composition in accordance with the presentinvention further comprises an antibacterial agent, such as a silversalt, an acceptable iodine source such as povidone iodine, chlorhexidinesalts such as the gluconate, actetate, hydrochloride or quaternaryantibacterial agents such as benzalkonium chloride or other antisepticsor antibiotics. The presence of antibacterial agents reduces the risk ofinfection. The composition in accordance with the present invention mayfurther comprise an osmolarity increasing agent such as urea, sodiumchloride and/or any salt or organic low molecular weight compound beingphysiological acceptable and non-irritating for adjusting the ionstrength of the coating approximately to the physiological range, thecoating preferably being isotonic in use. The composition in accordancewith the present invention may also comprise preservatives andpharmaceuticals, such as antimicrobial agents and antithrombogenicagents, or plasticizers.

The medical device having a functional coating may be any device thatshould be able to move against body tissue, such as an inner wall of abody vessel or the outer surface of the eye. Preferably, the medicaldevice is a medical tubing, guidewire, canula, stent, stent graft,anastomotic connector, synthetic patch, lead electrode, needle, senor,surgical instrument, angioplastic balloon, wound drain, shunt, tubing,infusion sleeve, urethal insert, pellet, implant, blood oxygenator,pump, vascular graft, vascular access port, heart valve, annuloplastyring, suture, surgical clip, surgical staple, pacemaker, implantabledefibrillator, neurostimulator, orthopedic device, cerebrospinal fluidshunt, implantable drug pump, spinal cage, artificial disc, replacementdevice for nucleus pulposus, ear tube, intraocular lens, tubing used inminimally invasive surgery, catheter, such as an intraluminal catheter,e.g. a urinary or cardiovascular catheter. Preferably, the medicaldevice may be packed together with the composition in accordance withthe present invention, more preferably the medical device is contactedwith the composition or the wetting agent of the present invention, issterilized and is stored in the wetting agent as a ready-to-useassembly. In such a ready-to-use assembly, the medical device can beused directly after opening of the packaging.

The wetting is achieved by contacting the medical device and thecomposition or the wetting agent in accordance with the presentinvention. Contacting may be achieved by dipping, spraying, vaporizingthe composition or the wetting agent and contacting the device with thevaporized composition or wetting agent.

The composition in accordance with the present invention is able toprevent or retard degradation of functional coatings on a medicaldevice. The composition of the present invention can be easily preparedfrom non-toxic components and can be used for radiation sterilization.When used for sterilizing a medical device no degradation of thefunctional coating on the medical device from reactive species generatedduring exposure of radiation occurs in the presence of the compositionof the present invention.

Further, the composition in accordance with the present invention isalso able to prevent or retard hydrolytic degradation and isparticularly suitable for wetted environments.

The following examples further describe the present invention.

EXAMPLES General Procedure for the Preparation of the Propyl GallateSolutions:

Propyl Gallate is only slightly soluble in water, but with the additionof propylene glycol the solubility of propyl gallate increases.Propylene glycol has a great affinity to water and also is a viablealternative additive to glycerol from a costing perspective.

1. Using a standard disposable pipette, 5 g of propylene glycol orglycerol was placed in a 200 ml glass beaker.

2. 10 g of 0.9 wt % saline (9 g/L sodium chloride solution) was thenadded to the propylene glycol or glycerol.

3. 0.01 to 0.5 g of propyl gallate is added to the beaker and distilledwater or 0.9 wt % saline (9 g/L sodium chloride solution) was added toamount to 100 ml of solution.

4. Taking the beaker by hand, the contents was gently swirled for about2 minutes to promote mixing, resulting with the propyl gallate beingvisibly dissolved. This pre-mixing ratio of saline or water withpropylene glycol or glycerol delivers a method whereby heating of thebeaker is not required to achieve complete dissolution of the propylgallate. However, in the case where glycerol is employed, it may benecessary to add some heat to the solution in order to achieve fulldissolution of the propyl gallate. While the addition of glycerol todistilled water/water/saline increases the degree of dissolution anddissolution rate of propyl gallate, it is significantly less effectivethan propylene glycol. For that reason, it may be necessary to add heatwhen using glycerol, especially where relatively high concentration ofpropyl gallate is being considered (i.e. 0.15 to 0.5 wt % propylgallate).

5. Other additives such as polyvinylpyrrolidone (PVP; Sigma Aldrich;K60, 45% in H2O), surfactants such as Tween 20 and 80 (non-ionic agentsupplied by Sigma Aldrich), buffer solutions (pH 4.00 (20° C); citricacid/sodium hydroxide/hydrogen chloride supplied by Merck ChemicalsKGaA), may optionally be added after mixing of the propyl gallate hasbeen accomplished.

6. A magnetic stirrer bar was placed in the beaker and the beaker placedon a magnetic stirrer (IKA RT5 Magnetic Stirrer). The heat settings areset at zero and the rotation speed set between the 3 and 4 mark on thestirrer equipment. The contents are stirred slowly for an hour to ensurea homogenous solution.

The amounts of the components are shown in Tables 1 to 5 below.

General Procedure for the Preparation of the CMC Solutions:

Preparation of sodium carboxylmethyl cellulose (Na—CMC) Pre-Mix:

1. 100 g of deionized water was weighed and poured into a glass beaker.

2. The required amount of Na—CMC as specified by Tables 6 and 7 wasweighed.

3. The water was placed on a magnetic stirrer and the stirrer set to 80°C to promote the dispersion and dissolution of the Na—CMC powder.

4. The Na—CMC was slowly added over 2-3 hour period until dissolved intothe water (the mixing time may greatly reduce depending on the amount ofCMC required).

5. The mixture was allowed to cool to room temperature while stirring ofthe solution was maintained.

6. When the mixture has cooled, 5 g of buffer (pH 4) was added andstirring was continued for 15-30 minutes.

Preparation of Wetting Agent Pre-mix:

1. The correct amount of propyl gallate in accordance with Tables 6 and7 was weighed and placed into a 100 mL glass beaker.

2. 5 g of polypropylene glycol was added to the glass beaker containingthe propyl gallate.

3. In short succession, 9.5 mL of saline solution was added to the glassbeaker containing the mixture of propyl gallate and polypropyleneglycol.

4. The glass beaker and its contents was stirred by hand for 2 minutesuntil all the propyl gallate has visually dissolved in the liquidmixture.

5. Where specified in Table 6 for ultrasonic agitation of the mixture,immediately after adding the 9.5 mL of saline fluid to the propylgallate and polypropylene glycol mixture, this 100 mL glass beaker(containing all ingredients) was placed into an ultrasonic bath for 30seconds.

Combining Pre-mixes:

1. Wetting Agent Premix was added into the CMC Premix

2. The contents were stirred employing a magnetic stirrer with no heat

3. Stirring was permitted for 2 hours.

Other additives such as Tween 20 and 80 (non-ionic agent supplied bySigma Aldrich), buffer solutions (pH 4.00 (20° C); citric acid/sodiumhydroxide/hydrogen chloride supplied by Merck Chemicals KGaA), mayoptionally be added after mixing of the Na—CMC and/or propyl gallate hasbeen accomplished.

General Procedure for the Preparation of the Test Specimen:

Extruded polymer shafts reflecting a diameter of 4.5 mm with an ID of3.0 mm were selected for the testing. These shafts had been dipped andcured resulting with a uniform hydrophilic coating along the polymerictube substrate. It is important to ensure that the same processingparameters of dipping and UV curing of the coating was maintained so asto eliminate any variability in coating integrity. The shaft materialused for these series of trials was polyurethane block copolymers andplasticized polyvinyl chloride. The shafts were placed on a cutting mattand with a sharp blade; the polymeric coated tubes were cut to a lengthof approximately 200 mm. The distal end of the shaft was cut at an angleto distinguish the distal end form the proximal end (at the distal end,the coating tends to be slightly thicker and the angle cut providesinformation for the friction test operator). For all specimens preparedfor friction testing, latex gloves were worn during all handling andcutting steps to prevent contamination of the surfaces of specimensubstrates.

Friction Testing (Coefficient of Friction—COF):

1. The protocol test program option was selected to access the testparameters

2. The following information was inputted into the program:

-   -   a. Clamp force=300 g    -   b. Test Speed=180 mm/minute    -   c. Test distance=60 mm.    -   d. Repeated Friction Test Cycles=25    -   e. Speed=3 cm/s

3. A stainless steel mandrel of appropriate diameter to the inner lumenof the coated test specimen was inserted fully into the test specimen.The tube was positioned such that a clamp was placed on the section thathad a clean level cut (the angled tube cut faced towards the watercontainer of the friction testing machine).

4. The clamping pads were of 60 DURO supplied by Harland; (Part Number102149).

5. This test assembly was mounted onto the Harland Friction Tester FTS5000 after it had been calibrated.

6. A container was filled with water to a predetermined mark so that thecoated test specimen and clamps were submerged prior to testing. Theclamp section of the specimen remained out of the water while the angledcut end of the specimen was submerged in the water.

7. The test was started after 30 seconds had elapsed to ensure that thecoating was fully hydrated.

8. The force expressed into the clamps was automatically recorded in theform of a graph of gram force versus time.

9. After the test was completed, a reading of average gram force andmaximum gram force was presented by the instrument.

10. The COF was calculated by dividing the average gram force reading by300 grams

11. After each test, a wetted cloth was used to remove any residualcoating that may have accumulated on the pads.

Abbreviations:

PG=propyl gallate; supplied by Sigma Aldrich in the form of powderNa—CMC=sodium carboxymethyl cellulosePPG=propylene glycolDW=distilled water

Buffer:

HPCE grade buffer solution with a pH value of 4.0 at 25° C with aconcentration of 20 mM sodium citrate (supplied by Sigma Aldrich).

Results: Example 1: Propyl Gallate Solutions

a) Effects of Glycerol on Coating Integrity

TABLE 1 COF (Number of pH Friction Cycles; Dosage PG PVP PPG BufferCarrier Glycerol 300 g clamp force) (kGy) (wt %) (wt %) (wt %) (wt %)Solution (wt %) 0 5 10 20 25 45 0.2 5 0 0 DW 5 4.2 4.1 4.1 4.1 4.1 450.2 5 0 0 DW 0 4.5 4.3 4.3 4.3 4.3

b) Effects of PG Concentration on Coating Integrity

TABLE 2 COF (Number of pH Friction Cycles; Dosage PG PVP PPG BufferCarrier Glycerol 300 g clamp force) (kGy) (wt %) (wt %) (wt %) (wt %)Solution (wt %) 0 5 10 20 25 45 0 10 0 0 DW 5 30 90 120 160 190 45 0.210 0 0 DW 5 4 4.3 4.2 4.2 4.3 45 0.5 10 0 0 DW 5 4 4.3 4.3 4.3 4.3 450.2 5 0 0 DW 5 4.3 4.1 4.1 4.1 4.1

c) Effects of PG concentration on coating integrity

TABLE 3 COF (Number of pH Friction Cycles; Dosage PG PVP PPG BufferCarrier Glycerol 300 g clamp force) (kGy) (wt %) (wt %) (wt %) (wt %)Solution (wt %) 0 5 10 20 25 45 0 5 0 0 DW 0 30 70 130 170 220 45 0.2 50 0 DW 0 4.2 4.1 4.1 4.1 4.1

d) Effects of PPG concentration on coating integrity

TABLE 4 COF (Number of pH Friction Cycles; Dosage PG PVP PPG BufferCarrier Glycerol 300 g clamp force) (kGy) (wt %) (wt %) (wt %) (wt %)Solution (wt %) 0 5 10 20 25 45 0.2 0 0 4 (10) saline 0 8.0 6.0 6.0 6.06.0 45 0.2 0 5 4 (10) saline 0 6.0 4.5 4.5 4.5 4.5

e) Effects of carrier solution on coating integrity

TABLE 5 COF (Number of pH Friction Cycles; Dosage PG PVP PPG BufferCarrier Glycerol 300 g clamp force) (kGy) (wt %) (wt %) (wt %) (wt %)Solution (wt %) 0 5 10 20 25 45 0.2 0 5 4 (10) saline 0 5.0 4.5 4.5 4.54.6 45 0.2 0 5 4 (10) DW 0 7.0 7.0 6.5 6.5 6.5

As can be seen from the test results, in the absence of propyl gallate,the coefficient of friction (COF) is much higher than in the presence ofpropyl gallate. Furthermore, the COF increases with increase in thenumber of cycles. If propyl gallate is present, the COF is low andmaintains almost constant (Table 2, Table 3).

Furthermore, the COF can be adjusted by adding further additives or byselecting the carrier solution and/or the pH.

Example 2: CMC solutions:

Formulations based on propyl gallate (PG) and sodium carboxymethylcellulose (Na—CMC) were developed to further enhance the wetting agentperformance. The samples were prepared with polypropylene glycol andbuffer content maintained constant throughout the study to demonstratethe influence of the main stabilizing component ingredients, i.e. propylgallate and sodium carboxymethyl cellulose.

The coating integrity and hydrolytic stability of the coating weretested after subjecting the hydrated specimens to 45 kGy gammairradiation dosages. The primary objective of the wetting agent is toprotect the hydrated hydrophilic coating during the sterilization cyclesand secondarily, to provide hydrolytic stability to the coating,reflecting real-world shelf-life product indication.

The hydrolytic stability of the coating was assessed by interpreting thecoating frictional stability performance over the 25 frictional cyclesafter subjecting coated hydrated specimens to accelerated aging forperiods of 15 days (T15) and 30 days (T30), respectively, at an ageingtemperatures of 50° C. All specimens were subjected to 45 kGyirradiation dosages. Time Zero (T0) directly after exposure captures theisolated effects of gamma irradiation on the coating integrity.

TABLE 6 Stability of wetting agent formulations after 45 kGy exposureSample 1 Sample 2 Sample 3* Sample 4 PG (wt %) 0.02 0.20 0.02 0.10 PPG(wt %) 5.00 5.00 5.00 5.00 Na-CMC (wt %) 0.20 0 0.20 0.10 Buffer (wt %)5.00 5.00 5.00 5.00 T0 Meta-stable stable stable stable T15 Not stablestable stable stable T30 Meta-stable stable stable stable *= ultrasonicagitation; T0 = directly after exposure; T15 = after 15 days at 50° C.;T30 = after 30 days at 50° C.

After 15 days ageing at 50° C in a hydrated state after 45 kGy exposure,the data indicate that PG provides further stability within theformulation. When comparing Samples 1 and 3, the formulations areidentical, but Sample 3 was ultrasonically agitated to promote thedissolution of the propyl gallate (PG) and enhances the efficacy of thePG within the solution and coating. Comparing Sample 3 to Sample 5,suggests that 0.1 wt % of PG and 0.1 wt % of CMC are sufficient todeliver coating stability after irradiation and ageing of the productspecimens.

After 30 days ageing at 50° C in a hydrated state after 45 kGy exposure,the data highlights:

-   -   PG at concentrations of 0.2 wt % provide adequate stability        alone (Sample 2)    -   Ultrasonic agitation enhances the efficacy of PG dissolution        (Samples 1 and 3)    -   A relative low 1:1 ratio of PG to Na—CMC delivers adequate        coating stability (Sample 4).

Further developments were focused on increasing the percentage of Na—CMCwithin the formulation. The following results depict Na—CMCconcentrations of 2 wt % and 5 wt % and assessing the influence of PG.

TABLE 7 Stability of wetting agent formulations after 45 kGy exposureSample 5 Sample 6 Sample 7 Sample 8 PG (wt %) 0.20 0 0.02 0 PPG (wt %)5.00 5.00 5.00 5.00 Na-CMC (wt %) 2.00 2.00 5.00 5.00 Buffer (wt %) 5.005.00 5.00 5.00 T0 stable stable stable stable T15 stable stable stablestable T30 stable stable stable stable T0 = directly after exposure; T15= after 15 days at 50° C.; T30 = after 30 days at 50° C.

At T0 after 45 kGy exposure, all formulations exhibited optimum coatingfriction and wear characteristics. After 15 days ageing at 50° C in ahydrated state after 45 kGy exposure, all formulations exhibited optimumcoating friction and wear characteristics. After 30 days ageing at 50° Cin a hydrated state after 45 kGy exposure, all formulations exhibitedoptimum coating friction and wear characteristics.

Na—CMC delivers excellent stability to the coating and can be used inconjunction with low concentration of PG to further improve the coatingstability as indicated by results obtained in Tables 6 and 7.

1. A composition for preventing or retarding degradation of a functionalcoating on a medical device, comprising: carboxymethyl cellulose or aderivative or salt thereof.
 2. The composition of claim 1, comprising asodium salt of carboxymethyl cellulose.
 3. The composition of claim 1,wherein carboxymethyl cellulose or a derivative or salt thereof ispresent in an amount of 0.1% to 10% by weight based on a total weight ofthe composition.
 4. The composition of claim 1, further comprising anaqueous or oil based base solution or a lipid media or a combinationthereof.
 5. The composition of claim 4, wherein the aqueous basesolution is selected from a group consisting of distilled water,deionized water, reverse osmosis water, filtered water and a salinesolution.
 6. The composition of claim 4, wherein the aqueous basesolution is present in an amount of from 50% to 99.99% by weight, basedon a total weight of the composition.
 7. The composition of claim ,further comprising gallic acid or a derivative thereof selected from anester, amide or oxadiazole derivative of gallic acid, preferably propylgallate.
 8. The composition of claim 7, wherein gallic acid or aderivative thereof is present in an amount of 0.001% to 1% by weight,based on the total weight of the composition.
 9. The composition ofclaim 1, further comprising a stabilizer, a solution enhancer and/or abuffer solution.
 10. The composition of claim 9, wherein the buffersolution has a pH of from 2.0 to 7.4.
 11. The composition of claim 9,wherein the solution enhancer is selected from a group consisting ofethylene glycol, diethylene glycol, propylene glycol, and glycerol. 12.The composition of claim 11, wherein the solution enhancer is present inan amount of 0.1% to 49.8% by weight, based on the total weight of thecomposition.
 13. The composition of 1, comprising: 0.1% to 5% by weightof sodium carboxymethyl cellulose; 0% to 0.5% by weight of propylgallate; and 1% to 10% by weight of propylene glycol.
 14. A method ofpreventing or retarding degradation of a functional coating on a medicaldevice from reactive species generated during exposure of radiationand/or from hydrolytic degradation by contacting at least a portion ofthe functional coating with the composition of claim 1.